TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20141097
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment options including pharmacotherapy, implantable cardioverter‐defibrillators, cardiac resynchronization therapy, and heart transplantation.
Study: 9812646
Drug: Composite Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Danshen Droplet Pills (CDDP)
Study: 31976576
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral immunotherapy (OIT) with gradual increase to 53 mg/day for 1 year.
Study: 27480813
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy intervention (CBTi) delivered by health-care assistants (HCAs) plus usual care
Study: 20003316
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 2000 IU/day for 6 months
Study: 8066868
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml carbocaine 1%
Study: 8066868
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml isotonic NaCl (control)
Study: 3184334
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral clindamycin (150 mg/d)
Study: 4552431
Drug: Adrenaline (1/1,000)
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenaline (1/1,000) 0.5 ml
Study: 30770424
Drug: Genetically instrumented
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically instrumented vitamin D levels (increase of 10 nmol/L)
Study: 22041889
Drug: pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 20 mg once daily
Study: 11161416
Drug: Gemination at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemination at the root's end (e.g., SMM)
Study: 10423595
Drug: Dirithromycin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (two 250 mg tablets)
Study: 7957504
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose load
Study: 7957504
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g fat load
Study: 31264958
Drug: Topical IOP-lowering
Normalized name: Avena sativa flowering top
DrugBank: Avena sativa flowering top (DB14253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical IOP-lowering eyedrops (Medicine-1st)
Study: 11523315
Drug: Enalapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20 mg o.d.)
Study: 11523315
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg o.d.)
Study: 9761083
Drug: Niaspan alone
Normalized name: Niaspan
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan alone (median dose 2,000 mg)
Study: 26879374
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily
Study: 24323035
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus prednisone 5 mg twice daily
Study: 24461175
Drug: Multi-disciplinary treatment
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-disciplinary treatment group (n=63)
Study: 19473192
Drug: gluten-free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: gluten-free diet plus 6 mg budesonide daily
Study: 19473192
Drug: budesonide (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide (10-30 microg/mL) in vitro
Study: 15692317
Drug: PLAC (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLAC (0.3 g.kg(‐1) body mass CaCO3 + 1 g NaCl)
Study: 15692317
Drug: 0.3CIT (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3CIT (0.3 g.kg(‐1) body mass tri-sodium citrate)
Study: 15692317
Drug: 0.5CIT (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5CIT (0.5 g.kg(‐1) body mass tri-sodium citrate)
Study: 9745228
Drug: Sulbactam/cefoperazone (SBT/CPZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam/cefoperazone (SBT/CPZ) administered simultaneously with fosfomycin (FOM)
Study: 2116206
Drug: Intramuscular gold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular gold thiomalate
Study: 23395546
Drug: 840 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 840 mg/day DHA and 270 mg/day EPA from fish oil capsules
Study: 24568073
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil capsules)
Study: 21086216
Drug: Process-experiential emotion-focused
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process-experiential emotion-focused therapy
Study: 17094744
Drug: Forced IV
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced IV hydration with 2 L of normal saline over 2 hours
Study: 17094744
Drug: Minimal IV
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal IV hydration at 20 mL of normal saline per hour
Study: 15636426
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg/day for 4 months
Study: 11791121
Drug: Tamoxifen, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen, administered for 5 years
Study: 11791121
Drug: Multi-agent chemotherapy
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-agent chemotherapy of 4-6 months duration
Study: 7953984
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU of intranasal salmon calcitonin (sCT)
Study: 7953984
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of intranasal salmon calcitonin (sCT)
Study: 7953984
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of intranasal salmon calcitonin (sCT)
Study: 7953984
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU and 400 IU of intranasal salmon calcitonin (sCT) pooled
Study: 3699218
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate combined with dithranol and UVB
Study: 31863962
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of bisphosphonate pamidronate within the first ten days of burn injury
Study: 31863962
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of bisphosphonate pamidronate
Study: 31863962
Drug: Serum from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum from patients given single dose bisphosphonate
Study: 31863962
Drug: Antibody to
Normalized name: Antibody to HPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody to transforming growth factor beta (TGFβ)
Study: 29741773
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with weekly carboplatin (AUC 2) and paclitaxel (135 mg/m2), plus daily lapatinib (1000 mg) for 6 weeks followed by surgical resection.
Study: 29741773
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with weekly carboplatin and paclitaxel, plus daily lapatinib followed by surgical resection.
Study: 29741773
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and surgical resection followed by risk-adapted adjuvant therapy.
Study: 29741773
Drug: Surgery following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surgery following induction chemotherapy.
Study: 24990099
Drug: rhAd5 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhAd5 injection
Study: 24990099
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gene therapy)
Study: 12426859
Drug: Alpha1-adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1-adrenoceptor antagonists (alfuzosin, doxazosin, tamsulosin, terazosin)
Study: 12426859
Drug: Alpha1-adrenoceptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1-adrenoceptor antagonists
Study: 12426859
Drug: Alpha1-blockers
Normalized name: Thymosin alpha1 (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1-blockers
Study: 8537548
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human tissue plasminogen activator (rhtPA: 10 mg)
Study: 1691406
Drug: quinapril, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinapril, 5 mg twice daily (b.i.d.)
Study: 1691406
Drug: quinapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinapril, 10 mg b.i.d.
Study: 1691406
Drug: quinapril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinapril, 20 mg b.i.d.
Study: 1691406
Drug: quinapril (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: quinapril (dosage titrated to a maximum of 40 mg/day, 20 mg b.i.d.)
Study: 31270177
Drug: Standard Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oxygen Therapy (standard O2)
Study: 18410297
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/day for the first week, then 40 mg/day for the following 3 weeks)
Study: 16952654
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (100% O2 at 2.4 atmosphere absolute for 30 sessions)
Study: 16952654
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (1.3 atmosphere absolute, breathing normal air)
Study: 11125653
Drug: Multimedia form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia form administered by computer
Study: 11125653
Drug: Written form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written form administered by computer (computerized page-turner)
Study: 3884426
Drug: Ranitidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (0.3 g/day in 2 oral doses)
Study: 3884426
Drug: Cimetidine (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.6 g/day in 4 oral doses)
Study: 24576907
Drug: 2-dose (2D)
Normalized name: Hep A, ped/adol, 2 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose (2D) schedule of HPV-16/18 AS04-adjuvanted vaccine administered at M0,6
Study: 24576907
Drug: 3-dose (3D)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-dose (3D) schedule of HPV-16/18 AS04-adjuvanted vaccine administered at M0,1,6
Study: 24576907
Drug: 2-dose (2D)
Normalized name: Hep A, ped/adol, 2 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose (2D) schedule
Study: 24576907
Drug: 3-dose (3D)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-dose (3D) schedule
Study: 22348812
Drug: Air with
Normalized name: ReliOn True Metrix Air with Bluetooth Self Monitoring Blood Glucose Monitoring System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air with constant flow (1.5 L/min)
Study: 22348812
Drug: Oxygen with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen with constant flow (1.5 L/min)
Study: 22348812
Drug: Automated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated oxygen flow titration
Study: 20080288
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of periprostatic anesthesia and bilateral pudendal block (group 2)
Study: 12885708
Drug: NaFeEDTA-fortified fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA-fortified fish sauce (10 g with 5 mg Fe)
Study: 12885708
Drug: FeSO4-fortified fish
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4-fortified fish sauce (10 g with 5 mg Fe)
Study: 12885708
Drug: NaFeEDTA-fortified soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA-fortified soy sauce (10 g with 5 mg Fe)
Study: 12885708
Drug: FeSO4-fortified soy
Normalized name: SOY ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4-fortified soy sauce (10 g with 5 mg Fe)
Study: 12885708
Drug: Fish sauce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish sauce effect on iron absorption
Study: 1770152
Drug: Alprazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (mean daily dose: 5.0 ± 2.3 mg)
Study: 1770152
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean daily dose: 182.0 ± 60.5 mg)
Study: 6755764
Drug: Intravenous penbutolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous penbutolol
Study: 17023203
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g ascorbic acid daily for 4 weeks
Study: 15010185
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (HED and LED with SFU and CFU)
Study: 11236112
Drug: Atosiban (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (n = 363; intravenous (iv) bolus dose of 6.75 mg, then 300 microg/minute iv for 3h and 100 microg/min iv thereafter)
Study: 11236112
Drug: Beta-agonists (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-agonists (n = 379; ritodrine, salbutamol or terbutaline iv; dose titrated)
Study: 27261237
Drug: C1 inhibitor
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1 inhibitor concentrate
Study: 2511744
Drug: Flecainide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide treatment
Study: 4948416
Drug: Tetracycline, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline, 2 doses daily for 3 days
Study: 29520816
Drug: Self-assembling peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-assembling peptide matrix (SAPM) gel, applied ex-office over 1 week
Study: 26258927
Drug: Telehealth service
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth service delivery model with combined pharmacotherapy and behavior training
Study: 26258927
Drug: Telepsychiatrists' decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepsychiatrists' decision making regarding medication adjustments
Study: 26258927
Drug: Telepsychiatrists' fidelity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepsychiatrists' fidelity to chosen algorithms in medication management
Study: 24898318
Drug: Equine facilitated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine facilitated learning (EFL) program, 11 weeks, once-weekly 90-min sessions
Study: 20616418
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TT) comprising clarithromycin, amoxicillin, omeprazole [n=23]
Study: 20616418
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Nigella sativa + 40 mg omeprazole [n=21]
Study: 20616418
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g Nigella sativa + omeprazole [n=21]
Study: 20616418
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Nigella sativa + omeprazole [n=23]
Study: 18520829
Drug: Topical antiglaucoma
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiglaucoma medications (specific combinations include timolol + dorzolamide, timolol + dorzolamide + pilocarpine)
Study: 18520829
Drug: Topical antiglaucoma
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiglaucoma medications (timolol + dorzolamide)
Study: 18520829
Drug: Topical antiglaucoma
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiglaucoma medications (timolol + dorzolamide + pilocarpine)
Study: 18520829
Drug: Topical antiglaucoma
Normalized name: ANTIGLAUCOMA MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antiglaucoma medications
Study: 15784718
Drug: Low GH
Normalized name: DIMETHICONE 20 mg in 1 g / OCTINOXATE 75 mg in 1 g / OCTISALATE 30 mg in 1 g / OXYBENZONE 30 ug in 1 g TOPICAL STICK [Softlips Marshmallow Ghost]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low GH dose (0.033 mg/kg.d or 0.1 IU/kg.d)
Study: 15784718
Drug: High GH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High GH dose (0.067 mg/kg.d or 0.2 IU/kg.d)
Study: 15784718
Drug: GH (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (both low and high doses)
Study: 7955757
Drug: Antigranulocyte antibody
Normalized name: technetium (99mTc) antigranulocyte antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigranulocyte antibody imaging
Study: 3671899
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/8 h) for 3 days prior to ascent and continued for 15 days at altitude
Study: 30015697
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (40% fraction of inspired oxygen, 8 cm H2O CPAP)
Study: 30015697
Drug: COT (classic
Approvals — FDA: no, EMA: no, PMDA: no
Description: COT (classic oxygen therapy via facemask at 6 L/min)
Study: 28880902
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% + Clonidine 150μg/ml
Study: 23239151
Drug: Lapatinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,500 mg + pazopanib 800 mg (Cohort 1)
Study: 23239151
Drug: Lapatinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,500 mg (Cohort 1)
Study: 23239151
Drug: Lapatinib 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,500 mg (Cohort 2)
Study: 23239151
Drug: Lapatinib 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,000 mg + pazopanib 400 mg (Cohort 2)
Study: 23239151
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg (Cohort 2)
Study: 16706613
Drug: Enfuvirtide (T-20)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (T-20) treatment for 48 weeks
Study: 15841624
Drug: Placebo (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.0 mL vehicle)
Study: 11605178
Drug: Paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 6) on day 1 every 4 weeks
Study: 11605178
Drug: Paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 2) weekly for 3 weeks
Study: 11605178
Drug: Paclitaxel 150
Normalized name: paclitaxel 150 MG per 25 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 150 mg/m(2)/wk + carboplatin (AUC 2 per week) during the second 8-week cycle
Study: 11605178
Drug: Maintenance weekly
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance weekly paclitaxel after initial treatment
Study: 9663369
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Study: 9663369
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Study: 10480191
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of cerivastatin sodium
Study: 9663369
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg and 0.15 mg of cerivastatin sodium combined
Study: 21350425
Drug: Pantogam activ
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantogam activ (1800 mg/d)
Study: 12764909
Drug: Yishou Tiaozhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishou Tiaozhi Tablet (YSTZT) 4 tablets 3 times a day for 60 days
Study: 12764909
Drug: Zocor 1
Normalized name: Zocor 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zocor 1 tablet before sleep every evening for 60 days
Study: 11421893
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (grass pollen-specific allergy vaccine with MPL adjuvant)
Study: 9240319
Drug: Azathioprine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (1 mg/kg/day)
Study: 7506322
Drug: Carvedilol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25-50 mg o.d.)
Study: 7506322
Drug: Metoprolol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100-200 mg o.d.)
Study: 7506322
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Metoprolol (acute treatment)
Study: 7506322
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Carvedilol (acute treatment)
Study: 30178600
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 mg/d)
Study: 31733336
Drug: Twice-daily soak-and-seal
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily soak-and-seal (SS) baths for 15 to 20 minutes (wet method)
Study: 31733336
Drug: Twice-daily soak-and-seal
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily soak-and-seal (SS) baths (wet method)
Study: 30326947
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound therapy (3 MHz, 0.132 W/cm2, 1.3 W) applied daily for 4 hours over 6 weeks
Study: 30326947
Drug: Active ultrasound
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ultrasound therapy